Damaged liver kept for three days then used in successful transplant

·Breaking News Editor, Yahoo News UK
·3 min read
(PA)
A Swiss medical team have kept a liver alive outside a human body for three days. (PA)

A damaged human liver has been kept alive outside a human body for three days before being transplanted in a world first, researchers have said.

Normally an organ can only be kept for 12 hours if they are stored conventionally on ice and in commercially available perfusion machines.

A cancer patient on the Swiss transplant waiting list was given the choice of using a treated human liver after he spent years living with serious liver conditions, including end-stage liver disease and liver cancer.

A year on from the surgery, he is thriving without any signs of liver damage or organ rejection and remains healthy.

Researchers say the development may save lives because the technology could increase the number of livers available for transplant and allow surgery to be scheduled days in advance.

Read more: Scientists can finally explain why Uranus and Neptune are different colours

Surgeon Prof. Pierre-Alain Clavien and the patient leaving the hospital after a successful transplantation. (PA)
Surgeon Prof. Pierre-Alain Clavien and the patient leaving the hospital after the operation. (PA)

The organ was transplanted in May 2021 and the patient was able to leave hospital a few days later.

He said: “I am very grateful for the life-saving organ.

“Due to my rapidly progressing tumour, I had little chance of getting a liver from the waiting list within a reasonable period of time.”

There is an increasing gap between the demand for liver transplants and the small number of available organs.

Due to the traditionally short time an organ can be stored for, the number of organs that can be matched to transplant recipients is limited.

Pierre-Alain Clavien, director of the Department of Visceral Surgery and Transplantation at the University Hospital Zurich, and colleagues demonstrated the preservation of a human liver for three days outside of the body using a machine that performs a technique known as ex-situ normothermic perfusion.

Read more: Pet cats kill up to 270 million animals a year in UK alone - ‘Mini super predators’

The Wyss Zurich team connecting the donor liver to the perfusion machine. (PA
The Wyss Zurich team connecting the donor liver to the perfusion machine. (PA

This is when the organ is supplied with a blood substitute at normal body temperature while outside the body.

The machine mimics the human body as accurately as possible to provide ideal conditions for human livers.

According to the study, the team prepared the liver in the machine with various drugs, making it suitable for transplant even though it was originally not approved for the procedure.

The Liver4Life team found that the transplanted organ functioned normally, with minimal injury, as blood flow from internal blood vessels returned.

Basic immunosuppressants were only given during the first six weeks after the surgery.

Among other things, connecting the liver to the machine allows it to be treated with antibiotic or hormonal therapies and lengthy laboratory or tissue tests can be carried out without time pressure.

The Wyss Zurich team with the patient, (left to right) Matteo Müller, Prof. Mark Tibbitt, patient, Prof. Pierre-Alain Clavien, Lucia Bautista Borrego, Max Hefti and Richard Sousa Da Silva. (PA)
The Wyss Zurich team with the patient, (left to right) Matteo Müller, Prof. Mark Tibbitt, patient, Prof. Pierre-Alain Clavien, Lucia Bautista Borrego, Max Hefti and Richard Sousa Da Silva. (PA)

Prof Clavien said: “Our therapy shows that by treating livers in the perfusion machine, it is possible to alleviate the lack of functioning human organs and save lives.”

Mark Tibbitt, professor of macromolecular engineering at ETH Zurich, added: “The interdisciplinary approach to solving complex biomedical challenges embodied in this project is the future of medicine.

“This will allow us to use new findings even more quickly for treating patients.”

The findings are published in the Nature Biotechnology journal.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting